252 related articles for article (PubMed ID: 20954411)
21. [The pre- and postoperative monitoring of the immunological indices and tumor markers in colorectal carcinoma].
Iarŭmov N; Ignatov A; Viiachki I
Khirurgiia (Sofiia); 1998; 51(3):42-8. PubMed ID: 9974027
[TBL] [Abstract][Full Text] [Related]
22. The prognostic value of the serum neuron specific enolase and lactate dehydrogenase in small cell lung cancer patients receiving first-line platinum-based chemotherapy.
Liu X; Zhang W; Yin W; Xiao Y; Zhou C; Hu Y; Geng S
Medicine (Baltimore); 2017 Nov; 96(46):e8258. PubMed ID: 29145241
[TBL] [Abstract][Full Text] [Related]
23. Serum neuron-specific enolase as a tumor marker in the diagnosis and follow-up of small-cell lung cancer.
Pinson P; Joos G; Watripont P; Brusselle G; Pauwels R
Respiration; 1997; 64(1):102-7. PubMed ID: 9044484
[TBL] [Abstract][Full Text] [Related]
24. Serum tumor markers may precede instrumental response to chemotherapy in patients with metastatic cancer.
Massacesi C; Rocchi MB; Marcucci F; Pilone A; Galeazzi M; Bonsignori M
Int J Biol Markers; 2003; 18(4):295-300. PubMed ID: 14756546
[TBL] [Abstract][Full Text] [Related]
25. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
26. Are levels of pro-gastrin-releasing peptide or neuron-specific enolase at relapse prognostic factors after relapse in patients with small-cell lung cancer?
Hirose T; Okuda K; Yamaoka T; Ishida K; Kusumoto S; Sugiyama T; Shirai T; Ohnshi T; Ohmori T; Adachi M
Lung Cancer; 2011 Feb; 71(2):224-8. PubMed ID: 20537424
[TBL] [Abstract][Full Text] [Related]
27. Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels.
Abrams RA; Grochow LB; Chakravarthy A; Sohn TA; Zahurak ML; Haulk TL; Ord S; Hruban RH; Lillemoe KD; Pitt HA; Cameron JL; Yeo CJ
Int J Radiat Oncol Biol Phys; 1999 Jul; 44(5):1039-46. PubMed ID: 10421536
[TBL] [Abstract][Full Text] [Related]
28. A more objective staging of advanced prostate cancer--routine recognition of malignant endocrine structures: the assessment of serum TPS, PSA, and NSE values.
Tarle M; Frković-Grazio S; Kraljić I; Kovacić K
Prostate; 1994; 24(3):143-8. PubMed ID: 7509485
[TBL] [Abstract][Full Text] [Related]
29. Elevated germ cell markers in carcinoma of uncertain primary site do not predict response to platinum based chemotherapy.
Currow DC; Findlay M; Cox K; Harnett PR
Eur J Cancer; 1996 Dec; 32A(13):2357-9. PubMed ID: 9038622
[TBL] [Abstract][Full Text] [Related]
30. Safety and efficacy of a combination of docetaxel and cisplatin in patients with unknown primary cancer.
Mukai H; Katsumata N; Ando M; Watanabe T
Am J Clin Oncol; 2010 Feb; 33(1):32-5. PubMed ID: 19786850
[TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of early serum tumor marker half-life in metastatic testicular teratoma.
Stevens MJ; Norman AR; Dearnaley DP; Horwich A
J Clin Oncol; 1995 Jan; 13(1):87-92. PubMed ID: 7528272
[TBL] [Abstract][Full Text] [Related]
32. Multicentric phase II study of cisplatin and etoposide in patients with metastatic carcinoma of unknown primary.
Voog E; Merrouche Y; Trillet-Lenoir V; Lasset C; Peaud PY; Rebattu P; Negrier S
Am J Clin Oncol; 2000 Dec; 23(6):614-6. PubMed ID: 11202809
[TBL] [Abstract][Full Text] [Related]
33. Cancer of unknown primary: clinicopathologic correlations.
Blaszyk H; Hartmann A; Bjornsson J
APMIS; 2003 Dec; 111(12):1089-94. PubMed ID: 14678017
[TBL] [Abstract][Full Text] [Related]
34. Comparison of Tc-99m sestamibi, serum neuron-specific enolase and lactate dehydrogenase as predictors of response to chemotherapy in small cell lung cancer.
Lim SC; Park KO; Kim YC; Na KJ; Song H; Bom HS
Cancer Biother Radiopharm; 2000 Aug; 15(4):381-6. PubMed ID: 11041023
[TBL] [Abstract][Full Text] [Related]
35. Ca125 and neuron-specific enolase (NSE) as tumour markers for intra-abdominal desmoplastic small round-cell tumours.
Fizazi K; Farhat F; Theodore C; Rixe O; Le Cesne A; Comoy E; Le Chevalier T
Br J Cancer; 1997; 75(1):76-8. PubMed ID: 9000601
[TBL] [Abstract][Full Text] [Related]
36. Two cases of small cell carcinoma of the prostate.
Okada H; Gotoh A; Ogawa T; Arakawa S; Ohbayashi C; Kamidono S
Scand J Urol Nephrol; 1996 Dec; 30(6):503-8. PubMed ID: 9008036
[TBL] [Abstract][Full Text] [Related]
37. Liver metastases from cancer of unknown primary (CUPL): a retrospective analysis of presentation, management and prognosis in 49 patients and systematic review of the literature.
Lazaridis G; Pentheroudakis G; Fountzilas G; Pavlidis N
Cancer Treat Rev; 2008 Dec; 34(8):693-700. PubMed ID: 18584969
[TBL] [Abstract][Full Text] [Related]
38. [Utility of Multiple Increased Lung Cancer Tumor Markers in Treatment of Patients with Advanced Lung Adenocarcinoma].
Peng Y; Wang Y; Hao X; Li J; Liu Y; Wang H
Zhongguo Fei Ai Za Zhi; 2017 Oct; 20(10):690-694. PubMed ID: 29061216
[TBL] [Abstract][Full Text] [Related]
39. The significance of NSE and CEA as a differentiation marker for the cellular heterogeneity of small cell lung cancer.
Kobayashi S; Okada S; Hasumi T; Sato N; Fujimura S
Tohoku J Exp Med; 1999 Sep; 189(1):37-49. PubMed ID: 10622207
[TBL] [Abstract][Full Text] [Related]
40. Thymidine kinase 1 combined with CEA, CYFRA21-1 and NSE improved its diagnostic value for lung cancer.
Jiang ZF; Wang M; Xu JL
Life Sci; 2018 Feb; 194():1-6. PubMed ID: 29247745
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
